Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Crucible Therapeutics
Sheffield, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Pre-clinical stage company developing gene therapies and siRNA targeting SRSF1 to reduce toxic dipeptide repeat proteins in C9orf72-related ALS and FTD; advancing toward first-in-human trials with recent Innovate UK funding.
- Therapeutic areas
- Neurology
- Modalities
- Gene therapysiRNA
- Industry
- Biotech
02
Partnerships
Argobio StudioNorthern GritstoneCell and Gene Therapy CatapultInnovate UK
Beyond the preview
Go deeper on Crucible Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Crucible Therapeutics.